Boehringer Ingelheim patents expiration
1. Atrovent Hfa patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8474447 | BOEHRINGER INGELHEIM | Inhaler device |
Jan, 2030
(6 years from now) | |
Drugs and Companies using IPRATROPIUM BROMIDE ingredient
Market Authorisation Date: 27 November, 2004
Treatment: NA
Dosage: AEROSOL, METERED;INHALATION
ATROVENT HFA family patents
2. Combivent Respimat patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7284474 | BOEHRINGER INGELHEIM | Piston-pumping system having o-ring seal properties |
Aug, 2024
(8 months from now) | |
| US7896264 | BOEHRINGER INGELHEIM | Microstructured high pressure nozzle with built-in filter function |
May, 2025
(1 year, 5 months from now) | |
| US7396341 | BOEHRINGER INGELHEIM | Blocking device for a locking stressing mechanism having a spring-actuated output drive device |
Oct, 2026
(2 years from now) | |
| US9027967 | BOEHRINGER INGELHEIM | Device for clamping a fluidic component |
Mar, 2027
(3 years from now) | |
| US7837235 | BOEHRINGER INGELHEIM | Device for clamping a fluidic component |
Mar, 2028
(4 years from now) | |
| US8733341 | BOEHRINGER INGELHEIM | Atomizer and method of atomizing fluid with a nozzle rinsing mechanism |
Oct, 2030
(6 years from now) | |
Drugs and Companies using ALBUTEROL SULFATE; IPRATROPIUM BROMIDE ingredient
Market Authorisation Date: 07 October, 2011
Treatment: NA
Dosage: SPRAY, METERED;INHALATION
COMBIVENT RESPIMAT family patents
3. Gilotrif patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| USRE43431 | BOEHRINGER INGELHEIM | Quinazoline derivatives and pharmaceutical compositions containing them |
Jan, 2026
(2 years from now) | |
| US8426586 | BOEHRINGER INGELHEIM | Process for preparing amino crotonyl compounds |
Oct, 2029
(5 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
USRE43431 (Pediatric) | BOEHRINGER INGELHEIM | Quinazoline derivatives and pharmaceutical compositions containing them |
Jul, 2026
(2 years from now) | |
| US9539258 | BOEHRINGER INGELHEIM | Quinazoline derivatives for the treatment of cancer diseases |
Nov, 2026
(2 years from now) | |
|
US9539258 (Pediatric) | BOEHRINGER INGELHEIM | Quinazoline derivatives for the treatment of cancer diseases |
May, 2027
(3 years from now) | |
| US8545884 | BOEHRINGER INGELHEIM | Solid pharmaceutical formulations comprising BIBW 2992 |
Dec, 2029
(6 years from now) | |
|
US8426586 (Pediatric) | BOEHRINGER INGELHEIM | Process for preparing amino crotonyl compounds |
Apr, 2030
(6 years from now) | |
|
US8545884 (Pediatric) | BOEHRINGER INGELHEIM | Solid pharmaceutical formulations comprising BIBW 2992 |
Jun, 2030
(6 years from now) | |
| US10004743 | BOEHRINGER INGELHEIM | Process for drying of BIBW2992, of its salts and of solid pharmaceutical formulations comprising this active ingredient |
Jul, 2030
(6 years from now) | |
|
US10004743 (Pediatric) | BOEHRINGER INGELHEIM | Process for drying of BIBW2992, of its salts and of solid pharmaceutical formulations comprising this active ingredient |
Jan, 2031
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Jan 12, 2025 |
| M (M) | Apr 7, 2025 |
| Pediatric Exclusivity (PED) | Oct 7, 2025 |
Drugs and Companies using AFATINIB DIMALEATE ingredient
Market Authorisation Date: 12 July, 2013
Treatment: Treatment of patients with advanced (metastatic) non-small cell lung cancer whose disease progressed during or after platinum-based chemotherapy
Dosage: TABLET;ORAL
GILOTRIF family patents
4. Glyxambi patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7407955 | BOEHRINGER INGELHEIM | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
May, 2025
(1 year, 5 months from now) | |
| US7713938 | BOEHRINGER INGELHEIM | Crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments |
Apr, 2027
(3 years from now) | |
| US7579449 | BOEHRINGER INGELHEIM | Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture |
Aug, 2028
(4 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8178541 | BOEHRINGER INGELHEIM | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
Aug, 2023
(3 months ago) | |
| US8119648 | BOEHRINGER INGELHEIM | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
Aug, 2023
(3 months ago) | |
|
US7407955 (Pediatric) | BOEHRINGER INGELHEIM | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
Nov, 2025
(1 year, 11 months from now) | |
| US8883805 | BOEHRINGER INGELHEIM | Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines |
Nov, 2025
(1 year, 11 months from now) | |
|
US8883805 (Pediatric) | BOEHRINGER INGELHEIM | Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines |
May, 2026
(2 years from now) | |
| US9173859 | BOEHRINGER INGELHEIM | Uses of DPP IV inhibitors |
May, 2027
(3 years from now) | |
| US8673927 | BOEHRINGER INGELHEIM | Uses of DPP-IV inhibitors |
May, 2027
(3 years from now) | |
| US11033552 | BOEHRINGER INGELHEIM | DPP IV inhibitor formulations |
May, 2027
(3 years from now) | |
|
US7713938 (Pediatric) | BOEHRINGER INGELHEIM | Crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments |
Oct, 2027
(3 years from now) | |
|
US11033552 (Pediatric) | BOEHRINGER INGELHEIM | DPP IV inhibitor formulations |
Nov, 2027
(3 years from now) | |
|
US8673927 (Pediatric) | BOEHRINGER INGELHEIM | Uses of DPP-IV inhibitors |
Nov, 2027
(3 years from now) | |
|
US7579449 (Pediatric) | BOEHRINGER INGELHEIM | Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture |
Feb, 2029
(5 years from now) | |
| US8551957 | BOEHRINGER INGELHEIM | Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivate |
Oct, 2029
(5 years from now) | |
|
US8551957 (Pediatric) | BOEHRINGER INGELHEIM | Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivate |
Apr, 2030
(6 years from now) | |
| US11090323 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Apr, 2034
(10 years from now) | |
| US10258637 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Apr, 2034
(10 years from now) | |
| US9949998 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Jun, 2034
(10 years from now) | |
|
US10258637 (Pediatric) | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Oct, 2034
(10 years from now) | |
|
US11090323 (Pediatric) | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Oct, 2034
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M (M) | Mar 30, 2023 |
Drugs and Companies using EMPAGLIFLOZIN; LINAGLIPTIN ingredient
Market Authorisation Date: 30 January, 2015
Treatment: Method of treating type 2 diabetes mellitus by administering linagliptin in combination with empagliflozin (with or without insulin or a sulfonylurea); Method of treating type 2 diabetes mellitus by a...
Dosage: TABLET;ORAL
GLYXAMBI family patents
5. Jardiance patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7713938 | BOEHRINGER INGELHEIM | Crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments |
Apr, 2027
(3 years from now) | |
| US7579449 | BOEHRINGER INGELHEIM | Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture |
Aug, 2028
(4 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7713938 (Pediatric) | BOEHRINGER INGELHEIM | Crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments |
Oct, 2027
(3 years from now) | |
|
US7579449 (Pediatric) | BOEHRINGER INGELHEIM | Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture |
Feb, 2029
(5 years from now) | |
| US8551957 | BOEHRINGER INGELHEIM | Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivate |
Oct, 2029
(5 years from now) | |
|
US8551957 (Pediatric) | BOEHRINGER INGELHEIM | Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivate |
Apr, 2030
(6 years from now) | |
| US11666590 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Apr, 2034
(10 years from now) | |
| US11090323 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Apr, 2034
(10 years from now) | |
| US10258637 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Apr, 2034
(10 years from now) | |
| US9949997 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
May, 2034
(10 years from now) | |
| US9949998 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Jun, 2034
(10 years from now) | |
|
US10258637 (Pediatric) | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Oct, 2034
(10 years from now) | |
|
US11090323 (Pediatric) | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Oct, 2034
(10 years from now) | |
|
US9949997 (Pediatric) | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Nov, 2034
(10 years from now) | |
|
US9949998 (Pediatric) | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Dec, 2034
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population (NPP) | Jun 20, 2026 |
| New Indication (I) | Sep 21, 2026 |
| M (M) | Feb 24, 2025 |
| Pediatric Exclusivity (PED) | Aug 24, 2025 |
Drugs and Companies using EMPAGLIFLOZIN ingredient
Market Authorisation Date: 01 August, 2014
Treatment: Method of treating type 2 diabetes mellitus by administering linagliptin in combination with empagliflozin; Treatment and reduction of risk by administration of empagliflozin to adults with chronic ki...
Dosage: TABLET;ORAL
JARDIANCE family patents
6. Jentadueto patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7407955 | BOEHRINGER INGELHEIM | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
May, 2025
(1 year, 5 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8119648 | BOEHRINGER INGELHEIM | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
Aug, 2023
(3 months ago) | |
| US8178541 | BOEHRINGER INGELHEIM | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
Aug, 2023
(3 months ago) | |
|
US7407955 (Pediatric) | BOEHRINGER INGELHEIM | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
Nov, 2025
(1 year, 11 months from now) | |
| US8883805 | BOEHRINGER INGELHEIM | Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines |
Nov, 2025
(1 year, 11 months from now) | |
|
US8883805 (Pediatric) | BOEHRINGER INGELHEIM | Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines |
May, 2026
(2 years from now) | |
| US8673927 | BOEHRINGER INGELHEIM | Uses of DPP-IV inhibitors |
May, 2027
(3 years from now) | |
|
US8673927 (Pediatric) | BOEHRINGER INGELHEIM | Uses of DPP-IV inhibitors |
Nov, 2027
(3 years from now) | |
| US10022379 | BOEHRINGER INGELHEIM | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
Apr, 2029
(5 years from now) | |
| US9415016 | BOEHRINGER INGELHEIM | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
Apr, 2029
(5 years from now) | |
| US10973827 | BOEHRINGER INGELHEIM | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
Apr, 2029
(5 years from now) | |
|
US10973827 (Pediatric) | BOEHRINGER INGELHEIM | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
Oct, 2029
(5 years from now) | |
|
US9415016 (Pediatric) | BOEHRINGER INGELHEIM | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
Oct, 2029
(5 years from now) | |
|
US10022379 (Pediatric) | BOEHRINGER INGELHEIM | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
Oct, 2029
(5 years from now) | |
| US9155705 | BOEHRINGER INGELHEIM | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
May, 2030
(6 years from now) | |
| US8846695 | BOEHRINGER INGELHEIM | Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy comprising a DPP-IV inhibitor |
Jun, 2030
(6 years from now) | |
|
US9155705 (Pediatric) | BOEHRINGER INGELHEIM | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
Nov, 2030
(6 years from now) | |
|
US8846695 (Pediatric) | BOEHRINGER INGELHEIM | Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy comprising a DPP-IV inhibitor |
Dec, 2030
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M (M) | Jun 20, 2026 |
| Pediatric Exclusivity (PED) | Dec 20, 2026 |
Drugs and Companies using LINAGLIPTIN; METFORMIN HYDROCHLORIDE ingredient
Market Authorisation Date: 30 January, 2012
Treatment: Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor; Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor in co...
Dosage: TABLET;ORAL
JENTADUETO family patents
7. Jentadueto Xr patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7407955 | BOEHRINGER INGELHEIM | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
May, 2025
(1 year, 5 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8178541 | BOEHRINGER INGELHEIM | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
Aug, 2023
(3 months ago) | |
| US8119648 | BOEHRINGER INGELHEIM | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
Aug, 2023
(3 months ago) | |
|
US7407955 (Pediatric) | BOEHRINGER INGELHEIM | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
Nov, 2025
(1 year, 11 months from now) | |
| US8883805 | BOEHRINGER INGELHEIM | Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines |
Nov, 2025
(1 year, 11 months from now) | |
|
US8883805 (Pediatric) | BOEHRINGER INGELHEIM | Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines |
May, 2026
(2 years from now) | |
| US8673927 | BOEHRINGER INGELHEIM | Uses of DPP-IV inhibitors |
May, 2027
(3 years from now) | |
| US9173859 | BOEHRINGER INGELHEIM | Uses of DPP IV inhibitors |
May, 2027
(3 years from now) | |
|
US9173859 (Pediatric) | BOEHRINGER INGELHEIM | Uses of DPP IV inhibitors |
Nov, 2027
(3 years from now) | |
|
US8673927 (Pediatric) | BOEHRINGER INGELHEIM | Uses of DPP-IV inhibitors |
Nov, 2027
(3 years from now) | |
| US9415016 | BOEHRINGER INGELHEIM | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
Apr, 2029
(5 years from now) | |
| US10022379 | BOEHRINGER INGELHEIM | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
Apr, 2029
(5 years from now) | |
|
US10022379 (Pediatric) | BOEHRINGER INGELHEIM | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
Oct, 2029
(5 years from now) | |
|
US9415016 (Pediatric) | BOEHRINGER INGELHEIM | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
Oct, 2029
(5 years from now) | |
| US9155705 | BOEHRINGER INGELHEIM | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
May, 2030
(6 years from now) | |
|
US9155705 (Pediatric) | BOEHRINGER INGELHEIM | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
Nov, 2030
(6 years from now) | |
| US9555001 | BOEHRINGER INGELHEIM | Pharmaceutical composition and uses thereof |
Mar, 2033
(9 years from now) | |
|
US9555001 (Pediatric) | BOEHRINGER INGELHEIM | Pharmaceutical composition and uses thereof |
Sep, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M (M) | Jun 20, 2026 |
| Pediatric Exclusivity (PED) | Dec 20, 2026 |
Drugs and Companies using LINAGLIPTIN; METFORMIN HYDROCHLORIDE ingredient
Market Authorisation Date: 27 May, 2016
Treatment: Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor in combination with metformin and, optionally, a sulfonylurea; Method of treating type 2 diabetes melli...
Dosage: TABLET, EXTENDED RELEASE;ORAL
JENTADUETO XR family patents
8. Micardis patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8003679 | BOEHRINGER INGELHEIM | Use of inhibitors of the renin-angiotensin system |
Oct, 2022
(1 year, 1 month ago) | |
Drugs and Companies using TELMISARTAN ingredient
Market Authorisation Date: 10 November, 1998
Treatment: Treatment or prevention of stroke
Dosage: TABLET;ORAL
MICARDIS family patents
9. Mirapex Er patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7695734 | BOEHRINGER INGELHEIM | Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof |
Apr, 2028
(4 years from now) | |
| US8679533 | BOEHRINGER INGELHEIM | Pramipexole once-daily dosage form |
Sep, 2029
(5 years from now) | |
Drugs and Companies using PRAMIPEXOLE DIHYDROCHLORIDE ingredient
Market Authorisation Date: 19 February, 2010
Treatment: Treatment of parkinson's disease
Dosage: TABLET, EXTENDED RELEASE;ORAL
MIRAPEX ER family patents
10. Ofev patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7119093 | BOEHRINGER INGELHEIM | 3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulphonate and the use thereof as a pharmaceutical composition |
Feb, 2024
(2 months from now) | |
| US6762180 | BOEHRINGER INGELHEIM | Substituted indolines which inhibit receptor tyrosine kinases |
Oct, 2025
(1 year, 10 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10154990 | BOEHRINGER INGELHEIM | Medicaments for the treatment or prevention of fibrotic diseases |
Jan, 2026
(2 years from now) | |
|
US6762180 (Pediatric) | BOEHRINGER INGELHEIM | Substituted indolines which inhibit receptor tyrosine kinases |
Apr, 2026
(2 years from now) | |
|
US10154990 (Pediatric) | BOEHRINGER INGELHEIM | Medicaments for the treatment or prevention of fibrotic diseases |
Jul, 2026
(2 years from now) | |
| US10105323 | BOEHRINGER INGELHEIM | Pharmaceutical dosage form for immediate release of an indolinone derivative |
Jun, 2029
(5 years from now) | |
| US9907756 | BOEHRINGER INGELHEIM | Capsule pharmaceutical dosage form comprising a suspension formulation of an indolinone derivative |
Jun, 2029
(5 years from now) | |
|
US10105323 (Pediatric) | BOEHRINGER INGELHEIM | Pharmaceutical dosage form for immediate release of an indolinone derivative |
Dec, 2029
(6 years from now) | |
|
US9907756 (Pediatric) | BOEHRINGER INGELHEIM | Capsule pharmaceutical dosage form comprising a suspension formulation of an indolinone derivative |
Dec, 2029
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Sep 6, 2026 |
| New Indication (I) | Mar 9, 2023 |
| Pediatric Exclusivity (PED) | Mar 6, 2027 |
Drugs and Companies using NINTEDANIB ESYLATE ingredient
Market Authorisation Date: 15 October, 2014
Treatment: Use of nintedanib for slowing the rate of decline in pulmonary function in patients with systemic sclerosis-associated interstitial lung disease (ssc-ild)
Dosage: CAPSULE;ORAL
OFEV family patents
11. Pradaxa patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7932273 | BOEHRINGER INGELHEIM | 3-[(2-{[4-(hexyloxycarbonylaminoiminomethyl) phenylamino]methyl}-1-methyl-1H-benzimidazol-5-carbonyl)pyridin-2-ylamino]propionic acid ethylester methansulfonate and its use as a medicament |
Sep, 2025
(1 year, 9 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US6087380 (Pediatric) | BOEHRINGER INGELHEIM | Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions |
Jun, 2022
(1 year, 5 months ago) | |
| US9925174 | BOEHRINGER INGELHEIM | Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonyl-amino-imino-methyl)-phenylamino]-methyl}-1-methyl-1 H-benzimidazol acid ethyl ester and the salts thereof |
Jun, 2023
(5 months ago) | |
|
US9925174 (Pediatric) | BOEHRINGER INGELHEIM | Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonyl-amino-imino-methyl)-phenylamino]-methyl}-1-methyl-1 H-benzimidazol acid ethyl ester and the salts thereof |
Dec, 2023
(13 days from now) | |
|
US7932273 (Pediatric) | BOEHRINGER INGELHEIM | 3-[(2-{[4-(hexyloxycarbonylaminoiminomethyl) phenylamino]methyl}-1-methyl-1H-benzimidazol-5-carbonyl)pyridin-2-ylamino]propionic acid ethylester methansulfonate and its use as a medicament |
Mar, 2026
(2 years from now) | |
| US7866474 | BOEHRINGER INGELHEIM | Film container |
Aug, 2027
(3 years from now) | |
|
US7866474 (Pediatric) | BOEHRINGER INGELHEIM | Film container |
Mar, 2028
(4 years from now) | |
| US9034822 | BOEHRINGER INGELHEIM | Methods of using antibodies during anticoagulant therapy of dabigatran and/or related compounds |
Jan, 2031
(7 years from now) | |
|
US9034822 (Pediatric) | BOEHRINGER INGELHEIM | Methods of using antibodies during anticoagulant therapy of dabigatran and/or related compounds |
Jul, 2031
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication (I) | Jun 21, 2024 |
| Pediatric Exclusivity (PED) | Dec 21, 2024 |
Drugs and Companies using DABIGATRAN ETEXILATE MESYLATE ingredient
Market Authorisation Date: 19 October, 2010
Treatment: Method of reversing the anticoagulant effect of dabigatran using idarucizumab
Dosage: CAPSULE;ORAL
PRADAXA family patents
12. Spiriva patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7070800 | BOEHRINGER INGELHEIM | Inhalable powder containing tiotropium |
Jan, 2022
(1 year, 10 months ago) | |
|
US6908928 (Pediatric) | BOEHRINGER INGELHEIM | Crystalline tiotropium bromide monohydrate, processes for the preparation thereof, and pharmaceutical compositions |
Mar, 2022
(1 year, 8 months ago) | |
|
US7309707 (Pediatric) | BOEHRINGER INGELHEIM | Crystalline micronisate, process for the manufacture thereof and use thereof for the preparation of a medicament |
Mar, 2022
(1 year, 8 months ago) | |
|
US6777423 (Pediatric) | BOEHRINGER INGELHEIM | Crystalline tiotropium bromide monohydrate, processes for the preparation thereof, and pharmaceutical compositions |
Mar, 2022
(1 year, 8 months ago) | |
|
US7642268 (Pediatric) | BOEHRINGER INGELHEIM | Crystalline micronisate, process for the manufacture thereof and use thereof for the preparation of a medicament |
Mar, 2022
(1 year, 8 months ago) | |
|
USRE38912 (Pediatric) | BOEHRINGER INGELHEIM | Process for preparing powder formulations |
Apr, 2022
(1 year, 7 months ago) | |
|
US7070800 (Pediatric) | BOEHRINGER INGELHEIM | Inhalable powder containing tiotropium |
Jul, 2022
(1 year, 4 months ago) | |
| US8022082 | BOEHRINGER INGELHEIM | Method for the administration of an anticholinergic by inhalation |
Jan, 2026
(2 years from now) | |
|
US8022082 (Pediatric) | BOEHRINGER INGELHEIM | Method for the administration of an anticholinergic by inhalation |
Jul, 2026
(2 years from now) | |
| US7694676 | BOEHRINGER INGELHEIM | Dry powder inhaler |
Mar, 2027
(3 years from now) | |
|
US7694676 (Pediatric) | BOEHRINGER INGELHEIM | Dry powder inhaler |
Sep, 2027
(3 years from now) | |
| US9010323 | BOEHRINGER INGELHEIM | Inhaler and sieve for an inhaler |
Apr, 2030
(6 years from now) | |
Drugs and Companies using TIOTROPIUM BROMIDE ingredient
Market Authorisation Date: 30 January, 2004
Treatment: For the long-term, once-daily, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (copd), including chronic bronchitis and emphysema; Administration of an inha...
Dosage: POWDER;INHALATION
SPIRIVA family patents
13. Spiriva Respimat patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7988001 (Pediatric) | BOEHRINGER INGELHEIM | Container provided with a pressure equalization opening |
Feb, 2022
(1 year, 9 months ago) | |
| US7284474 | BOEHRINGER INGELHEIM | Piston-pumping system having o-ring seal properties |
Aug, 2024
(8 months from now) | |
|
US7284474 (Pediatric) | BOEHRINGER INGELHEIM | Piston-pumping system having o-ring seal properties |
Feb, 2025
(1 year, 2 months from now) | |
| US7896264 | BOEHRINGER INGELHEIM | Microstructured high pressure nozzle with built-in filter function |
May, 2025
(1 year, 5 months from now) | |
|
US7896264 (Pediatric) | BOEHRINGER INGELHEIM | Microstructured high pressure nozzle with built-in filter function |
Nov, 2025
(1 year, 11 months from now) | |
| US7396341 | BOEHRINGER INGELHEIM | Blocking device for a locking stressing mechanism having a spring-actuated output drive device |
Oct, 2026
(2 years from now) | |
| US9027967 | BOEHRINGER INGELHEIM | Device for clamping a fluidic component |
Mar, 2027
(3 years from now) | |
|
US7396341 (Pediatric) | BOEHRINGER INGELHEIM | Blocking device for a locking stressing mechanism having a spring-actuated output drive device |
Apr, 2027
(3 years from now) | |
|
US9027967 (Pediatric) | BOEHRINGER INGELHEIM | Device for clamping a fluidic component |
Oct, 2027
(3 years from now) | |
| US7837235 | BOEHRINGER INGELHEIM | Device for clamping a fluidic component |
Mar, 2028
(4 years from now) | |
|
US7837235 (Pediatric) | BOEHRINGER INGELHEIM | Device for clamping a fluidic component |
Sep, 2028
(4 years from now) | |
| US8733341 | BOEHRINGER INGELHEIM | Atomizer and method of atomizing fluid with a nozzle rinsing mechanism |
Oct, 2030
(6 years from now) | |
|
US8733341 (Pediatric) | BOEHRINGER INGELHEIM | Atomizer and method of atomizing fluid with a nozzle rinsing mechanism |
Apr, 2031
(7 years from now) | |
Drugs and Companies using TIOTROPIUM BROMIDE ingredient
Market Authorisation Date: 24 September, 2014
Treatment: NA
Dosage: SPRAY, METERED;INHALATION
SPIRIVA RESPIMAT family patents
14. Stiolto Respimat patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7491719 | BOEHRINGER INGELHEIM | Enantiomerically pure beta agonists, process for the manufacture thereof, and use thereof as medicaments |
Nov, 2023
(20 days ago) | |
| US7056916 | BOEHRINGER INGELHEIM | Medicaments for the treatment of chronic obstructive pulmonary disease |
Dec, 2023
(6 days from now) | |
| US7220742 | BOEHRINGER INGELHEIM | Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments |
May, 2025
(1 year, 5 months from now) | |
| US7727984 | BOEHRINGER INGELHEIM | Medicaments for the treatment of chronic obstructive pulmonary disease |
Jan, 2027
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7786111 | BOEHRINGER INGELHEIM | Medicaments for the treatment of chronic obstructive pulmonary disease |
Nov, 2023
(20 days ago) | |
| US8044046 | BOEHRINGER INGELHEIM | Medicaments for the treatment of chronic obstructive pulmonary disease |
Nov, 2023
(20 days ago) | |
| US7284474 | BOEHRINGER INGELHEIM | Piston-pumping system having o-ring seal properties |
Aug, 2024
(8 months from now) | |
|
US7284474 (Pediatric) | BOEHRINGER INGELHEIM | Piston-pumping system having o-ring seal properties |
Feb, 2025
(1 year, 2 months from now) | |
| US8034809 | BOEHRINGER INGELHEIM | Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments |
May, 2025
(1 year, 5 months from now) | |
| US7896264 | BOEHRINGER INGELHEIM | Microstructured high pressure nozzle with built-in filter function |
May, 2025
(1 year, 5 months from now) | |
| US7396341 | BOEHRINGER INGELHEIM | Blocking device for a locking stressing mechanism having a spring-actuated output drive device |
Oct, 2026
(2 years from now) | |
| US9027967 | BOEHRINGER INGELHEIM | Device for clamping a fluidic component |
Mar, 2027
(3 years from now) | |
|
US7396341 (Pediatric) | BOEHRINGER INGELHEIM | Blocking device for a locking stressing mechanism having a spring-actuated output drive device |
Apr, 2027
(3 years from now) | |
| US7837235 | BOEHRINGER INGELHEIM | Device for clamping a fluidic component |
Mar, 2028
(4 years from now) | |
|
US7837235 (Pediatric) | BOEHRINGER INGELHEIM | Device for clamping a fluidic component |
Sep, 2028
(4 years from now) | |
| US8733341 | BOEHRINGER INGELHEIM | Atomizer and method of atomizing fluid with a nozzle rinsing mechanism |
Oct, 2030
(6 years from now) | |
Drugs and Companies using OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE ingredient
Market Authorisation Date: 21 May, 2015
Treatment: Treatment of copd; Treatment of respiratory complaints
Dosage: SPRAY, METERED;INHALATION
STIOLTO RESPIMAT family patents
15. Striverdi Respimat patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7491719 | BOEHRINGER INGELHEIM | Enantiomerically pure beta agonists, process for the manufacture thereof, and use thereof as medicaments |
Nov, 2023
(20 days ago) | |
| US7056916 | BOEHRINGER INGELHEIM | Medicaments for the treatment of chronic obstructive pulmonary disease |
Dec, 2023
(6 days from now) | |
| US7220742 | BOEHRINGER INGELHEIM | Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments |
May, 2025
(1 year, 5 months from now) | |
| US7727984 | BOEHRINGER INGELHEIM | Medicaments for the treatment of chronic obstructive pulmonary disease |
Jan, 2027
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8044046 | BOEHRINGER INGELHEIM | Medicaments for the treatment of chronic obstructive pulmonary disease |
Nov, 2023
(20 days ago) | |
| US7786111 | BOEHRINGER INGELHEIM | Medicaments for the treatment of chronic obstructive pulmonary disease |
Nov, 2023
(20 days ago) | |
| US7284474 | BOEHRINGER INGELHEIM | Piston-pumping system having o-ring seal properties |
Aug, 2024
(8 months from now) | |
| US8034809 | BOEHRINGER INGELHEIM | Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments |
May, 2025
(1 year, 5 months from now) | |
| US7896264 | BOEHRINGER INGELHEIM | Microstructured high pressure nozzle with built-in filter function |
May, 2025
(1 year, 5 months from now) | |
| US7396341 | BOEHRINGER INGELHEIM | Blocking device for a locking stressing mechanism having a spring-actuated output drive device |
Oct, 2026
(2 years from now) | |
| US9027967 | BOEHRINGER INGELHEIM | Device for clamping a fluidic component |
Mar, 2027
(3 years from now) | |
| US7837235 | BOEHRINGER INGELHEIM | Device for clamping a fluidic component |
Mar, 2028
(4 years from now) | |
| US8733341 | BOEHRINGER INGELHEIM | Atomizer and method of atomizing fluid with a nozzle rinsing mechanism |
Oct, 2030
(6 years from now) | |
Drugs and Companies using OLODATEROL HYDROCHLORIDE ingredient
Market Authorisation Date: 31 July, 2014
Treatment: Treatment of chronic obstructive pulmonary disease (copd), chronic bronchitis or emphysema
Dosage: SPRAY, METERED;INHALATION
STRIVERDI RESPIMAT family patents
16. Synjardy patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7713938 | BOEHRINGER INGELHEIM | Crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments |
Apr, 2027
(3 years from now) | |
| US7579449 | BOEHRINGER INGELHEIM | Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture |
Aug, 2028
(4 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7713938 (Pediatric) | BOEHRINGER INGELHEIM | Crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments |
Oct, 2027
(3 years from now) | |
|
US7579449 (Pediatric) | BOEHRINGER INGELHEIM | Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture |
Feb, 2029
(5 years from now) | |
| US10610489 | BOEHRINGER INGELHEIM | Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof |
Sep, 2030
(6 years from now) | |
|
US10610489 (Pediatric) | BOEHRINGER INGELHEIM | Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof |
Mar, 2031
(7 years from now) | |
| US10258637 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Apr, 2034
(10 years from now) | |
| US11090323 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Apr, 2034
(10 years from now) | |
| US9949997 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
May, 2034
(10 years from now) | |
|
US11090323 (Pediatric) | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Oct, 2034
(10 years from now) | |
|
US10258637 (Pediatric) | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Oct, 2034
(10 years from now) | |
|
US9949997 (Pediatric) | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Nov, 2034
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population (NPP) | Jun 20, 2026 |
| Pediatric Exclusivity (PED) | Dec 20, 2026 |
Drugs and Companies using EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient
Market Authorisation Date: 26 August, 2015
Treatment: Method of treating type 2 diabetes mellitus in a patient with renal impairment (45 ml/min/1.73 m2<=egfr<60 ml/min/1.73 m2) by once daily administration of 10 mg or 25 mg of empagliflozin; Method of tr...
Dosage: TABLET;ORAL
SYNJARDY family patents
17. Synjardy Xr patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7713938 | BOEHRINGER INGELHEIM | Crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments |
Apr, 2027
(3 years from now) | |
| US7579449 | BOEHRINGER INGELHEIM | Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture |
Aug, 2028
(4 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7713938 (Pediatric) | BOEHRINGER INGELHEIM | Crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments |
Oct, 2027
(3 years from now) | |
|
US7579449 (Pediatric) | BOEHRINGER INGELHEIM | Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture |
Feb, 2029
(5 years from now) | |
| US10596120 | BOEHRINGER INGELHEIM | Pharmaceutical compositions |
Mar, 2032
(8 years from now) | |
|
US10596120 (Pediatric) | BOEHRINGER INGELHEIM | Pharmaceutical compositions |
Sep, 2032
(8 years from now) | |
| US10258637 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Apr, 2034
(10 years from now) | |
| US11090323 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Apr, 2034
(10 years from now) | |
| US9949997 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
May, 2034
(10 years from now) | |
| US9949998 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Jun, 2034
(10 years from now) | |
|
US11090323 (Pediatric) | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Oct, 2034
(10 years from now) | |
|
US10258637 (Pediatric) | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Oct, 2034
(10 years from now) | |
|
US9949997 (Pediatric) | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Nov, 2034
(10 years from now) | |
|
US9949998 (Pediatric) | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Dec, 2034
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M (M) | Jun 20, 2026 |
| Pediatric Exclusivity (PED) | Dec 20, 2026 |
Drugs and Companies using EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient
Market Authorisation Date: 09 December, 2016
Treatment: Treatment of a type 2 diabetes mellitus patient with insufficient glycemic control despite metformin therapy using a composition comprising an extended release core comprising metformin and an outer c...
Dosage: TABLET, EXTENDED RELEASE;ORAL
SYNJARDY XR family patents
18. Tradjenta patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7407955 | BOEHRINGER INGELHEIM | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
May, 2025
(1 year, 5 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8119648 | BOEHRINGER INGELHEIM | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
Aug, 2023
(3 months ago) | |
| US8178541 | BOEHRINGER INGELHEIM | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
Aug, 2023
(3 months ago) | |
|
US7407955 (Pediatric) | BOEHRINGER INGELHEIM | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
Nov, 2025
(1 year, 11 months from now) | |
| US8883805 | BOEHRINGER INGELHEIM | Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines |
Nov, 2025
(1 year, 11 months from now) | |
|
US8883805 (Pediatric) | BOEHRINGER INGELHEIM | Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines |
May, 2026
(2 years from now) | |
| US8673927 | BOEHRINGER INGELHEIM | Uses of DPP-IV inhibitors |
May, 2027
(3 years from now) | |
| US11033552 | BOEHRINGER INGELHEIM | DPP IV inhibitor formulations |
May, 2027
(3 years from now) | |
|
US11033552 (Pediatric) | BOEHRINGER INGELHEIM | DPP IV inhibitor formulations |
Nov, 2027
(3 years from now) | |
|
US8673927 (Pediatric) | BOEHRINGER INGELHEIM | Uses of DPP-IV inhibitors |
Nov, 2027
(3 years from now) | |
| US10034877 | BOEHRINGER INGELHEIM | Treatment for diabetes in patients inappropriate for metformin therapy |
Aug, 2029
(5 years from now) | |
| US9486526 | BOEHRINGER INGELHEIM | Treatment for diabetes in patients inappropriate for metformin therapy |
Aug, 2029
(5 years from now) | |
|
US10034877 (Pediatric) | BOEHRINGER INGELHEIM | Treatment for diabetes in patients inappropriate for metformin therapy |
Feb, 2030
(6 years from now) | |
|
US9486526 (Pediatric) | BOEHRINGER INGELHEIM | Treatment for diabetes in patients inappropriate for metformin therapy |
Feb, 2030
(6 years from now) | |
| US8846695 | BOEHRINGER INGELHEIM | Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy comprising a DPP-IV inhibitor |
Jun, 2030
(6 years from now) | |
|
US8846695 (Pediatric) | BOEHRINGER INGELHEIM | Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy comprising a DPP-IV inhibitor |
Dec, 2030
(7 years from now) | |
| US8853156 | BOEHRINGER INGELHEIM | Treatment for diabetes in patients inappropriate for metformin therapy |
Mar, 2031
(7 years from now) | |
|
US8853156 (Pediatric) | BOEHRINGER INGELHEIM | Treatment for diabetes in patients inappropriate for metformin therapy |
Sep, 2031
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M (M) | Jun 20, 2026 |
| Pediatric Exclusivity (PED) | Dec 20, 2026 |
Drugs and Companies using LINAGLIPTIN ingredient
Market Authorisation Date: 02 May, 2011
Treatment: Method of treating type 2 diabetes mellitus by administering linagliptin in combination with insulin (with or without metformin and/or pioglitazone); Method of treating type 2 diabetes mellitus by adm...
Dosage: TABLET;ORAL
TRADJENTA family patents
19. Trijardy Xr patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7407955 | BOEHRINGER INGELHEIM | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
May, 2025
(1 year, 5 months from now) | |
| US7713938 | BOEHRINGER INGELHEIM | Crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments |
Apr, 2027
(3 years from now) | |
| US7579449 | BOEHRINGER INGELHEIM | Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture |
Aug, 2028
(4 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8119648 | BOEHRINGER INGELHEIM | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
Aug, 2023
(3 months ago) | |
| US8178541 | BOEHRINGER INGELHEIM | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
Aug, 2023
(3 months ago) | |
|
US7407955 (Pediatric) | BOEHRINGER INGELHEIM | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
Nov, 2025
(1 year, 11 months from now) | |
| US8883805 | BOEHRINGER INGELHEIM | Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines |
Nov, 2025
(1 year, 11 months from now) | |
|
US8883805 (Pediatric) | BOEHRINGER INGELHEIM | Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines |
May, 2026
(2 years from now) | |
|
US7713938 (Pediatric) | BOEHRINGER INGELHEIM | Crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments |
Oct, 2027
(3 years from now) | |
|
US7579449 (Pediatric) | BOEHRINGER INGELHEIM | Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture |
Feb, 2029
(5 years from now) | |
| US10022379 | BOEHRINGER INGELHEIM | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
Apr, 2029
(5 years from now) | |
| US9415016 | BOEHRINGER INGELHEIM | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
Apr, 2029
(5 years from now) | |
| US8551957 | BOEHRINGER INGELHEIM | Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivate |
Oct, 2029
(5 years from now) | |
|
US8551957 (Pediatric) | BOEHRINGER INGELHEIM | Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivate |
Apr, 2030
(6 years from now) | |
| US9155705 | BOEHRINGER INGELHEIM | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
May, 2030
(6 years from now) | |
| US10406172 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Jun, 2030
(6 years from now) | |
| US10596120 | BOEHRINGER INGELHEIM | Pharmaceutical compositions |
Mar, 2032
(8 years from now) | |
| US11564886 | BOEHRINGER INGELHEIM | Pharmaceutical compositions |
Mar, 2032
(8 years from now) | |
| US10258637 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Apr, 2034
(10 years from now) | |
| US11090323 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Apr, 2034
(10 years from now) | |
| US9949998 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Jun, 2034
(10 years from now) | |
|
US10258637 (Pediatric) | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Oct, 2034
(10 years from now) | |
|
US11090323 (Pediatric) | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Oct, 2034
(10 years from now) | |
|
US9949998 (Pediatric) | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Dec, 2034
(11 years from now) | |
Drugs and Companies using EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE ingredient
Market Authorisation Date: 27 January, 2020
Treatment: Method of treating type 2 diabetes mellitus by administering linagliptin in combination with empagliflozin and metformin; Method of treating type 2 diabetes using a pharmaceutical composition comprisi...
Dosage: TABLET, EXTENDED RELEASE;ORAL
TRIJARDY XR family patents
20. Viramune Xr patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8460704 | BOEHRINGER INGELHEIM | Extended release formulation of nevirapine |
Mar, 2029
(5 years from now) | |
Drugs and Companies using NEVIRAPINE ingredient
Market Authorisation Date: 25 March, 2011
Treatment: Treatment of hiv-1 by once daily administration
Dosage: TABLET, EXTENDED RELEASE;ORAL
VIRAMUNE XR family patents